Edwards Lifesciences (NYSE:EW) reported fourth-quarter sales of $1.39 billion, beating the consensus of $1.36 billion. This ...

Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter and full-year ended Dec. 31, 2024.

Over the last two decades, Edwards Lifesciences has demonstrated that it knows how to maintain leadership through innovation of tissue heart valves. Edwards remains the dominant force in surgical ...

Investors remain bullish on medical device makers, expecting them to benefit from still-high demand for surgical procedures, ...

Q4 2024 Earnings Call Transcript February 11, 2025 Edwards Lifesciences Corporation beats earnings expectations. Reported EPS ...

Edwards Lifesciences stock popped Wednesday on strong sales of its TAVR procedures, leading to a top- and bottom-line beat.

Edwards Lifesciences Corporation (NYSE:EW) develops medical innovations for heart disease and critical care monitoring. Its ...

Edwards Lifesciences (NYSE:EW – Get Free Report) had its price objective upped by Morgan Stanley from $70.00 to $75.00 in a report issued on Wednesday,Benzinga reports. The firm currently has an ...

Bleakley Financial Group LLC lowered its stake in Edwards Lifesciences Co. (NYSE:EW – Free Report) by 5.3% during the 4th ...

Women are often underdiagnosed and undertreated when it comes to heart disease, particularly conditions like aortic stenosis.

Edwards Lifesciences Corp.’s posted fourth quarter results slightly ahead of expectations, but indicated that the first quarter of 2025 might not be as bright. The company expects growth for both its ...

Edwards Lifesciences Corp Larry Wood; Corporate Vice President - Transcatheter Aortic Valve Replacement; Edwards Lifesciences Corp Greetings, and welcome to the Edwards Lifesciences Corporation fourth ...